Home > Insider Trading > Filing (0001104659-20-085988)

Filing Details

Accession Number:: 0001104659-20-085988
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-07-23 16:16:17
Reporting Period:: 2020-07-21

Accepted Time:: 2020-07-23 16:16:17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1609550	Inspire Medical Systems Inc.	INSP	Surgical & Medical Instruments & Apparatus (3841)	261377674

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1737133	Richard Buchholz	C/O Inspire Medical Systems, Inc. 5500 Wayzata Blvd., Suite 1600 Golden Valley MN 55416	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-21	3,000	$2.07	34,068	No	4	M	Direct
Common Stock	Disposition	2020-07-21	2,100	$99.02	31,968	No	4	S	Direct
Common Stock	Disposition	2020-07-21	900	$100.20	31,068	No	4	S	Direct
Common Stock	Acquisiton	2020-07-22	1,463	$0.94	32,531	No	4	M	Direct
Common Stock	Acquisiton	2020-07-22	3,628	$0.94	36,159	No	4	M	Direct
Common Stock	Acquisiton	2020-07-22	22,706	$2.07	58,865	No	4	M	Direct
Common Stock	Acquisiton	2020-07-22	12,687	$10.38	71,552	No	4	M	Direct
Common Stock	Acquisiton	2020-07-22	1,952	$42.15	73,504	No	4	M	Direct
Common Stock	Disposition	2020-07-22	1,120	$0.00	72,384	No	5	G	Direct
Common Stock	Acquisiton	2020-07-22	280	$0.00	880	No	5	G	Indirect	By Daughter
Common Stock	Acquisiton	2020-07-22	280	$0.00	880	No	5	G	Indirect	By Son
Common Stock	Acquisiton	2020-07-22	280	$0.00	880	No	5	G	Indirect	By Son
Common Stock	Acquisiton	2020-07-22	280	$0.00	880	No	5	G	Indirect	By Son

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	5	G	Direct
No	5	G	Indirect	By Daughter
No	5	G	Indirect	By Son
No	5	G	Indirect	By Son
No	5	G	Indirect	By Son

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-21	3,000	$0.00	3,000	$2.07
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-22	1,463	$0.00	1,463	$0.94
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-22	3,628	$0.00	3,628	$0.94
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-22	22,706	$0.00	22,706	$2.07
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-22	12,687	$0.00	12,687	$10.38
Common Stock	Stock Option (Right to Buy)	Disposition	2020-07-22	1,952	$0.00	1,952	$42.15

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
22,706	2024-06-01	No	4	M	Direct
752	2027-01-01	No	4	M	Direct
2,215	2027-04-01	No	4	M	Direct
0	2024-06-01	No	4	M	Direct
9,869	2028-04-09	No	4	M	Direct
23,048	2028-12-18	No	4	M	Direct

Footnotes

Includes 197 shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan since the date of the reporting person's last ownership report.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.96 to $99.69. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.03 to $100.53. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option is fully vested and exercisable.
This option grant was previously reported as having an expiration date of May 31, 2024, which has been revised herein.
The option vested and became exercisable as to 25% of the underlying shares on January 1, 2018 and has vested or will vest and become exercisable with respect to the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
This option grant was previously reported as having an expiration date of December 31, 2026, which has been revised herein.
The option vested and became exercisable as to 25% of the underlying shares on April 1, 2018 and has vested or will vest and become exercisable with respect to the remaining 75% of the award in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
This option grant was previously reported as having an expiration date of March 31, 2027, which has been revised herein.
The option vested and became exercisable as to 25% of the underlying shares on April 9, 2019 and has vested or will vest and become exercisable with respect to the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
This option grant was previously reported as having an expiration date of April 8, 2028, which has been revised herein.
The option vested and became exercisable as to 25% of the underlying shares on December 18, 2019 and has vested or will vest and become exercisable with respect to the remaining 75% of the underlying shares in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.